Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose is a monosaccharide that provides calories and may induce osmotic diuresis. Sodium chloride is an electrolyte that maintains fluid and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving diuretics or with conditions leading to potassium loss,Source of calories (dextrose) and electrolytes (sodium, chloride) in parenteral nutrition
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion at a rate not exceeding 10 m Eq/hour and concentration not exceeding 40 m Eq/L. Typical adult dose is 10-20 m Eq administered over 1-2 hours, repeated as needed based on serum potassium levels. Maximum daily dose is usually 200 m Eq.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
The terminal elimination half-life of potassium is not classically defined due to tight homeostatic regulation; however, the biological half-life for exchangeable potassium in the body is approximately 30 days (range 20-40 days) in adults, reflecting slow turnover of intracellular stores. Clinical context: acute shifts from IV infusion are rapidly distributed, with redistribution half-life of ~1-2 hours, but total body elimination depends on renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the Krebs cycle. Sodium and chloride are not metabolized but are excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion. Fecal elimination accounts for <10%, mainly through gastrointestinal secretion. Biliary excretion is negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Potassium is not significantly bound to plasma proteins; protein binding is negligible (<1%).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
The apparent volume of distribution (Vd) for potassium is approximately 0.5-0.7 L/kg, reflecting distribution primarily in the extracellular fluid (ECF) and exchange with intracellular fluid (ICF). Clinical meaning: The large Vd (total body water) indicates extensive tissue distribution; only ~2% of total body potassium is in ECF.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: Approximately 90-100% of potassium chloride is absorbed from the gastrointestinal tract. Intravenous: 100% bioavailability (direct administration into systemic circulation). Note: For potassium chloride in a parenteral solution, only IV administration is relevant; bioavailability is 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 25-50% and monitor serum potassium closely. GFR <10 m L/min: avoid use or use with extreme caution; maximum dose 20 m Eq per day with continuous monitoring.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25% and monitor serum potassium. Child-Pugh Class C: avoid use due to risk of hyperkalemia and altered potassium homeostasis.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion: 0.5-1 m Eq/kg/dose, not to exceed 40 m Eq/dose. Administer at a rate not exceeding 0.5-1 m Eq/kg/hour. Maximum concentration 40 m Eq/L. Adjust based on serum potassium levels.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at low end of dosing range due to decreased renal function. Maximum infusion rate 5 m Eq/hour. Monitor renal function and serum potassium frequently. Avoid in patients with significant renal impairment.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Potassium chloride concentrate must be diluted and used only in patients with adequate urine flow. Rapid infusion may cause hyperkalemia and cardiac arrest. Do not administer undiluted.
None.
Risk of hyperkalemia: monitor serum potassium and renal function, especially in patients with renal impairment, heart disease, or on potassium-sparing diuretics,Extravasation may cause tissue necrosis,Use with caution in patients with heart failure, severe renal impairment, or adrenal insufficiency,Monitor for signs of fluid overload (especially in patients with compromised cardiovascular function)
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Severe renal impairment with oliguria or anuria,Addison's disease,Acute dehydration,Heat cramps,Concurrent use of potassium-sparing diuretics (e.g., spironolactone, eplerenone),Hypersensitivity to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, tomatoes) unless directed by your doctor. Also avoid salt substitutes containing potassium chloride. No restrictions with alcohol or caffeine.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects have been reported at therapeutic doses. Inadvertent hyperkalemia, hyperglycemia, or hypernatremia may cause fetal distress. Risk is minimal when used as indicated.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, dextrose, and sodium chloride are normal constituents of breast milk. No adverse effects on nursing infant expected at maternal therapeutic doses. M/P ratio for potassium is approximately 1.0. Use caution with high maternal doses.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may increase volume of distribution and renal clearance of potassium. However, dosing adjustments are not routinely required; individualize based on serum potassium levels. Dextrose may require monitoring in gestational diabetes. Sodium chloride adjustments generally not needed unless hypernatremia or hyponatremia occurs.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This combination is used for maintenance fluid therapy with potassium supplementation. Monitor serum potassium closely to avoid hyperkalemia, especially in patients with renal impairment, concurrent ACE inhibitors, or potassium-sparing diuretics. Rate of infusion should not exceed 10 m Eq/hour of potassium. In dextrose-containing solutions, monitor blood glucose. Use with caution in patients with heart failure or edema due to sodium content.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to maintain fluid and electrolyte balance.,Report any muscle weakness, tingling, or irregular heartbeat immediately.,Do not consume potassium supplements or salt substitutes without consulting your doctor.,Inform your doctor if you have kidney problems, diabetes, or heart conditions.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose is a monosaccharide that provides calories and may induce osmotic diuresis. Sodium chloride is an electrolyte that maintains fluid and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/hour and concentration not exceeding 40 m Eq/L. Typical adult dose is 10-20 m Eq administered over 1-2 hours, repeated as needed based on serum potassium levels. Maximum daily dose is usually 200 m Eq.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects have been reported at therapeutic doses. Inadvertent hyperkal. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.